QuidelOrtho (NASDAQ:QDEL) Announces Quarterly Earnings Results

QuidelOrtho (NASDAQ:QDEL) released its quarterly earnings results on Thursday. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18, FiscalAI reports. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The firm had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same quarter in the previous year, the company posted $0.12 EPS. The business’s revenue was up 2.8% on a year-over-year basis. QuidelOrtho updated its FY 2026 guidance to 0.650-0.900 EPS.

Here are the key takeaways from QuidelOrtho’s conference call:

• Underlying business remained resilient: Q2 revenue grew 6% excluding China, with strength across labs, immunohematology, TRIAGE, and major regions outside China.
• Adjusted EBITDA rose 21% to $129 million, while EBITDA margin expanded 310 basis points to 20%, reflecting productivity improvements and disciplined expense management.
• China revenue declined 23% amid uncertainty over proposed IVD pricing guidelines, and management expects the resulting demand pressure to persist through the remainder of 2026.
• The company lowered 2026 guidance to revenue of $2.52 billion–$2.60 billion, adjusted EBITDA of $540 million–$560 million, and adjusted EPS of $0.65–$0.90, while withdrawing free cash flow guidance because of market and working-capital uncertainty.
• Management said the NULEXA point-of-care molecular platform remains on track for commercialization, with encouraging early customer engagement and expected momentum ahead of the 2027–2028 respiratory season.

QuidelOrtho Stock Down 6.7%

Shares of NASDAQ:QDEL traded down $1.18 during midday trading on Thursday, hitting $16.32. 2,729,745 shares of the company’s stock were exchanged, compared to its average volume of 1,756,714. The stock has a 50 day moving average price of $15.77 and a 200-day moving average price of $17.59. The company has a market cap of $1.11 billion, a PE ratio of -0.92 and a beta of 0.68. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its stake in QuidelOrtho by 3,691.7% in the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares during the period. EverSource Wealth Advisors LLC increased its holdings in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after acquiring an additional 2,309 shares during the period. Osaic Holdings Inc. increased its holdings in shares of QuidelOrtho by 298.1% in the second quarter. Osaic Holdings Inc. now owns 3,300 shares of the company’s stock worth $95,000 after purchasing an additional 2,471 shares during the period. Finally, State of Wyoming increased its stake in QuidelOrtho by 230.5% in the 2nd quarter. State of Wyoming now owns 4,524 shares of the company’s stock worth $130,000 after acquiring an additional 3,155 shares during the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on QDEL shares. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. Finally, Citigroup upped their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $13.62.

QuidelOrtho News Roundup

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, well above the $0.04–$0.05 loss analysts expected and ahead of $0.12 per share a year earlier. Revenue reached $631 million, exceeding the approximately $619 million consensus estimate. QuidelOrtho Q2 earnings and revenue estimates
• Positive Sentiment: Revenue grew 3% year over year, or 2% in constant currency, led by the Labs and Point-of-Care businesses. Excluding China, revenue growth was stronger at 6% on both a reported and constant-currency basis, suggesting underlying demand remains relatively healthy. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Options-market activity showed elevated implied volatility ahead of the earnings release, indicating that investors anticipated a potentially significant post-results move. Implied volatility for QuidelOrtho options
• Negative Sentiment: QuidelOrtho lowered its fiscal 2026 outlook to $0.65–$0.90 in EPS, versus analyst expectations near $1.85, and projected revenue of $2.5–$2.6 billion, below the roughly $2.7 billion consensus. The substantial guidance gap raises concerns about slower growth or profitability pressure during the remainder of the year. QuidelOrtho full-year 2026 guidance
• Negative Sentiment: The company continues to report a deeply negative net margin, reinforcing investor concerns that the earnings beat may not represent a durable improvement in overall profitability.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.